Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report
Year: 2025
Type: article
Study design: Case Report
Abstract: The use of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of many malignancies. However, they may be associated with life-threatening immune-mediated adverse effects.In this article, we present the case of a patient diagnosed with stage IIB acral melanoma (pT4aN0M0) who started adjuvant treatment with pembrolizumab, after which he developed severe myocarditis with myositis and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod.The use of Efgartigimod resulted in a remarkable recovery, marking the first reported acute application of this agent for IM3OS and positive anti-acetylcholine receptor antibodies (anti-AChR).
Source: Immunotherapy
Institution: Hospital Juan Ramón Jiménez
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4411255385